Abstract
Introduction/BackgroundBRCA mutations and HR deficient (HRD) status influences the magnitude of PARP-inhibitors (PARP-i) benefit over Progression Free Survival and therefore are important factors in ovarian cancer diagnosis and treatment decisions....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Paper Title
Journal
Date
